UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 2.651

Sortiert nach

A model for individualized risk prediction of contralateral breast cancer

Breast cancer research and treatment, 2017-01, Vol.161 (1), p.153-160

2017

Link zum Volltext

Verfügbarkeit prüfen

Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial

Breast cancer research and treatment, 2022-04, Vol.192 (3), p.593-602

2022

Link zum Volltext

Verfügbarkeit prüfen

TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li–Fraumeni family

Breast cancer research and treatment, 2015-06, Vol.151 (3), p.671-678

2015

Link zum Volltext

Verfügbarkeit prüfen

Long-term outcomes of breast-conserving therapy for women with ductal carcinoma in situ

Breast cancer research and treatment, 2019-12, Vol.178 (3), p.607-615

2019

Link zum Volltext

Verfügbarkeit prüfen

Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients

Breast cancer research and treatment, 2010-01, Vol.119 (2), p.367-377

2010

Link zum Volltext

Verfügbarkeit prüfen

Dose-dependent effect of mammographic breast density on the risk of contralateral breast cancer

Breast cancer research and treatment, 2018-07, Vol.170 (1), p.143-148

2018

Link zum Volltext

Verfügbarkeit prüfen

Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women

Breast cancer research and treatment, 2019-02, Vol.173 (3), p.657-665

2019

Link zum Volltext

Verfügbarkeit prüfen

Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer

Breast cancer research and treatment, 2017-11, Vol.166 (1), p.145-156

2017

Link zum Volltext

Verfügbarkeit prüfen

Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature

Breast cancer research and treatment, 2010-02, Vol.120 (1), p.119-126

2010

Link zum Volltext

Verfügbarkeit prüfen

Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype

Breast cancer research and treatment, 2012-11, Vol.136 (1), p.153-160

2012

Link zum Volltext

Verfügbarkeit prüfen

A randomized trial of interpersonal psychotherapy, problem solving therapy, and supportive therapy for major depressive disorder in women with breast cancer

Breast cancer research and treatment, 2019-01, Vol.173 (2), p.353-364

2019

Link zum Volltext

Verfügbarkeit prüfen

Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider–patient communication

Breast cancer research and treatment, 2013-02, Vol.137 (3), p.829-836

2013

Link zum Volltext

Verfügbarkeit prüfen

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)

Breast cancer research and treatment, 2016-11, Vol.160 (2), p.297-304

2016

Link zum Volltext

Verfügbarkeit prüfen

Impact of chemotherapy, radiotherapy, and endocrine therapy on sick leave in women with early-stage breast cancer during a 5-year period: a population-based cohort study

Breast cancer research and treatment, 2020-08, Vol.182 (3), p.699-707

2020

Link zum Volltext

Verfügbarkeit prüfen

Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy

Breast cancer research and treatment, 2019-08, Vol.177 (1), p.61-66

2019

Link zum Volltext

Verfügbarkeit prüfen

Breast conserving surgery in combination with intraoperative radiotherapy after previous external beam therapy: an option to avoid mastectomy

Breast cancer research and treatment, 2018-04, Vol.168 (3), p.739-744

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy

Breast cancer research and treatment, 2018-04, Vol.168 (2), p.357-364

2018

Link zum Volltext

Verfügbarkeit prüfen

Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set

Breast cancer research and treatment, 2019-01, Vol.173 (2), p.455-463

2019

Link zum Volltext

Verfügbarkeit prüfen

Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2)

Breast cancer research and treatment, 2017-07, Vol.164 (2), p.359-369

2017

Link zum Volltext

Verfügbarkeit prüfen

HER2-targeted therapy influences CTC status in metastatic breast cancer

Breast cancer research and treatment, 2020-07, Vol.182 (1), p.127-136

2020

Link zum Volltext

Verfügbarkeit prüfen

Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy

Breast cancer research and treatment, 2017, Vol.161 (1), p.173-179

2017

Link zum Volltext

Verfügbarkeit prüfen

Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy

Breast cancer research and treatment, 2019-08, Vol.176 (3), p.709-716

2019

Link zum Volltext

Verfügbarkeit prüfen

Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study

Breast cancer research and treatment, 2012-05, Vol.133 (1), p.367-373

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy

Breast cancer research and treatment, 2018-09, Vol.171 (2), p.371-381

2018

Link zum Volltext

Verfügbarkeit prüfen

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study

Breast cancer research and treatment, 2019-06, Vol.175 (3), p.595-603

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 2.651

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieBreast Cancer Research And Treatment

ThemaAdult

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.651)
Mit Volltextzugriff
(2.651)

Publikationsform

Artikel
(2.651)

Sprache

Englisch
(2.651)
Japanisch
(399)
Russisch
(5)
Norwegisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(2.651)
Oncology
(2.646)
Life Sciences & Biomedicine
(2.632)
Science & Technology
(2.632)
Female
(2.609)
Middle Aged
(2.544)
Breast Cancer
(2.525)
Aged
(2.089)
Medicine
(2.089)
Medicine & Public Health
(2.087)
Tumors
(1.576)
Biological And Medical Sciences
(1.502)
Medical Sciences
(1.502)
Gynecology. Andrology. Obstetrics
(1.393)
Mammary Gland Diseases
(1.393)
Breast Neoplasms - Pathology
(1.363)
Cancer
(1.217)
Aged, 80 And Over
(958)
Breast Neoplasms - Drug Therapy
(891)

14 weitere anzeigen...

Weniger anzeigen...

Kollektion

SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(2.651)
MEDLINE
(2.651)
WK Lippincott Williams & Wilkins–Connect here FIRST to enable access
(2.651)
SpringerLink Journals - AutoHoldings
(2.651)
IngentaConnect Journals
(228)
IngentaConnect Journals
(2)
Free E-Journal (出版社公開部分のみ）
(1)
Springer Nature - Connect here FIRST to enable access
(1)

3 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

A model for individualized risk prediction of contralateral breast cancer

Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial

TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li–Fraumeni family

Long-term outcomes of breast-conserving therapy for women with ductal carcinoma in situ

Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients

Dose-dependent effect of mammographic breast density on the risk of contralateral breast cancer

Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women

Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer

Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature

Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype

A randomized trial of interpersonal psychotherapy, problem solving therapy, and supportive therapy for major depressive disorder in women with breast cancer

Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider–patient communication

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)

Impact of chemotherapy, radiotherapy, and endocrine therapy on sick leave in women with early-stage breast cancer during a 5-year period: a population-based cohort study

Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy

Breast conserving surgery in combination with intraoperative radiotherapy after previous external beam therapy: an option to avoid mastectomy

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy

Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set

Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2)

HER2-targeted therapy influences CTC status in metastatic breast cancer

Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy

Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy

Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study

Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study

Aktive Filter

Suchergebnisse filtern